参考文献/References:
[1] 戴璟,闵杰青,杨云娟.中国九省市成年人血脂异常流行特点研究[J].中华心血管病杂志,2018,46(2):114-118.
[2]Sierra-Johnson J,Fisher RM,Romero-Corra A,et al.Concentration of apolipoprotein B is comparable with the apolipoprotein B/ apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality:findings from a multi-ethnic US population [J].Eur Heart, 2009,30(6):710-717.
[3] Li Y,Yin R,Zhou Y,et al.Associations of the apolipoprotein A-I gene polymorphism and serum lipid levels in the Guangxi Hei Yi Zhuang and Han populations [J].Int J Mol Med,2008,21(6):753-764.
[4] 黄冲,唐朝克.影响高密度脂蛋白胆固醇水平的相关基因研究进展[J].中南医学科学杂志,2017,45(3):299-302.
[5] Walldius G,Jungner I.The apoB/apoA-I ratio:a strong,new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence [J].Intern Med,2006,259(5):493-519.
[6] Andrikoula M,McDowell IF.The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment [J].Diabetes Obes Metab,2008,10(4):271-278.
[7] Rasheed H, Phipps-Green AJ,Topless R,et al.Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout [J].Rheumatology (Oxford),2016,55(8):1421-1430.
[8] Li Y, Li C,Gao J.Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis [J].Meta Gene,2016,9:104-109.
[9] Cui F, Li K,Li Y,et al.Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population [J].Lipids Health Dis,2014,13:170.
[10] Chhabra S, Narang R, Krishnan LR,et al.Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians [J].BMC Genet,2002,3:9.
[11]Yu J, Huang J, Liang Y,et al. Lack of association between apolipoprotein C3 gene polymorphisms and risk of coronary heart disease in a Han population in East China [J].Lipids Health Dis,2011,10:200.
[12]Stan S,Delvin E,Lambert M,et al. Apo A-IV:An update on regulation and physiologic functions [J].Biochim Biophys Acta,2003,1631 (2):177-187.
[13]Forte TM,Ryan RO.Apolipoprotein A5:extracellular and intracellular roles in triglyceride metabolism[J].Curr Drug Targets ,2015,16(12):1274-1280.
[14] 田卫东,庞广杰,李俊,等.载脂蛋白基因多态性与冠心病易感性的研究进展[J].中国循证心血管医学杂志,2014,06(3):372-374.
[15]Yuan S,Ma YT,Xie X ,et al.Association between apolipoprotein A5 gene polymorphism and coronary heart disease in the Han population from Xinjiang [J].Zhonghua Liu Xing Bing Xue Za Zhi ,2011,32(1):51-54.
[16]Zhang J,Wan DG,Song HL,et al.APOA5 -1131T/C polymorphism and coronary artery disease susceptibility in Chinese population: an updated meta-analysis and review[J].Genet Mol Res,2015,14(4):12330-12339.
[17] Yang G, Lei MM, Yu CL,et al.Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case–control and meta-analysis study [J].Lipids Health Dis,2015,14:113.
[18]Yuan S,Ma YT,Xie X,et al.Association of apolipoprotein A5 gene polymorphism with coronary heart disease in Uygur population of Xinjiang[J].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011,28(1):73-77.
[19] Hamon SC, Kardia SL, Boerwinkle E,et al.Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene cluster[J].Hum Hered,2006,61(2):87-96.
[20]侯彦宏,聂波,沈晓旭.载脂蛋白E基因敲除小鼠在动脉粥样硬化研究中的应用[J].心血管病学进展,2017,38(6):679-683.
[21]李歆，徐韫健，罗娥.华南地区汉族人群SLCO1B1和apoＥ基因多态性分析[J].检验医学与临床,2017,14(6):773-775.
[22]Chaudhary R,Likidlilid A,Peerapatdit T,et al. Apolipoprotein E gene polymorphism:effects on plasma lipids and risk of type 2 diabetes and coronary artery disease[J].Cardiovasc Diabetol,2012,11:36.
[23]Shewan LG,Coats AJS. Ethics in the authorship and publishing of scientific articles[J].Int J Cardiol,2010,144(1):1-2.
[24]郑文武,李正业,李翔,等.阿托伐他汀对不同ApoE基因型冠心病患者血脂调控影响的临床研究[J].检验医学与临床,2015,12(18):2671-2673.
[25]Bennet AM,di Angelantonio E,Wensley F,et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk[J]JAMA,2007,298(11):1300-1311.
[26] Zhang MD,Gu W,Qiao SB,et al. Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population:a meta-analysis of 61 studies including 6 634 cases and 6 393 controls[J].PLoS One,2014,9(4): e95463.
[27] Xu M, Zhao J, Zhang Y,et al. Apolipoprotein E gene variants and risk of coronary heart disease: a meta-analysis[J].Biomed Res Int,2016,2016:3912175.
[28]Larifla L,Armand C,Bangou J,et al.Association of APOE gene polymorphism with lipid profile and coronary artery disease in Afro-Caribbeans[J].PLoS One,2017,12(7): e0181620.
[29] Lagor WR,Fields DW,Khetarpal SA,et al.The effects of apolipoprotein F deficiency on high density lipoprotein cholesterol metabolism in mice[J].PLoS One,2012,7(2): e31616.
[30] Leduc MS, Shimmin LC,Klos KL,et al.Comprehensive evaluation of apolipoprotein H gene (APOH) variation identifies novel associations with measures of lipid metabolism in GENOA [J].J Lipid Res,2008,49(12):2648-2656.
[31]李琴.冠心病患者载脂蛋白L-I基因Ile244Met位点多态性的研究[C].2016:38-38.
[32]Pan JP,Wei SL,Chiang SC,et al. Association of apolipoprotein J polymorphism 1598delT with coronary artery disease and lipoprotein levels [J].Cardiology,2011,118(2):83-92.
[33] Zhang Y,Huang LZ,Liu Y,et al.Correlation analysis between ApoM gene-promoter polymorphisms and coronary heart disease [J].Cardiovasc J Afr ,2016,27(4):228-237.
[34]Huang LZ,Gao JL,Pu C,et al. Apolipoprotein M: research progress, regulation and metabolic functions (Review)[J].Mol Med Rep,2015,12(2):1617-1624.
[35]Zheng L,Luo G,Zhang J,et al. Decreased activities of apolipoprotein M promoter are associated with the susceptibility to coronary artery diseases[J].Int J Med Sci,2014,11(4):365-372.
[36]Saleheen D,Haycock PC,Zhao W,et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease:a mendelian randomisation analysis[J].Lancet Diabetes Endocrinol,2017,5(7): 524-533.
[37]Zhu L,L Z,Song YY.Advances in the association between apolipoprotein (a) gene polymorphisms and coronary heart disease[J].Zhongguo Yi Xue Ke Xue Yuan Xue Bao,2015,37(4):482-488.
相似文献/References:
[1]陈元 楚天舒 武力勇.瘦素抵抗、瘦素受体基因多态性与冠状动脉粥样硬化性心脏病的相关性进展[J].心血管病学进展,2019,(8):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
CHEN Yuan,CHU Tianshu,WU Liyong.Leptin Resistance,Leptin Receptor Gene Polymorphism and Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
[2]臧童童 沈雳.基因多态性与心力衰竭发生和发展的研究进展[J].心血管病学进展,2021,(6):516.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.010]
ZANG TongtongSHEN Li.The Relationship Between Gene Polymorphism and Heart Failure[J].Advances in Cardiovascular Diseases,2021,(9):516.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.010]
[3]曾庆媛 文舒 吕瑜玫 王明义.维生素D及其代谢通路基因多态性与妊娠期高血压疾病相关性研究进展[J].心血管病学进展,2022,(11):1033.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.016]
ZENG Qingyuan,WEN Shu,LV Yumei,et al.The Correlation Between Vitamin D and Its Metabolic Pathway Gene Polymorphism and Hypertensive Disorder of Pregnancy[J].Advances in Cardiovascular Diseases,2022,(9):1033.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.016]
[4]雷悦云 邵磊 高传玉 张优.早发冠心病发病机制相关基因多态性研究进展[J].心血管病学进展,2023,(4):331.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
LEI Yueyun,SHAO Lei,GAO Chuanyu,et al.Gene Polymorphisms related to the Pathogenesis of?remature Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2023,(9):331.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
[5]张毅 顾铭霞.ADRB1、ACE基因多态性与左心室肥厚的相关性研究[J].心血管病学进展,2023,(7):664.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.020]
ZHANG Yi,GU Mingxia.The Relationship of Gene Polymorphism in the 1-Adrenergic Receptor and Angiotensin Converting Enzyme with Left Ventricular Hypertrophy[J].Advances in Cardiovascular Diseases,2023,(9):664.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.020]
[6]李俊 李春霞 陈瑞瑞 张夏林 杨志明.载脂蛋白C3在代谢性心血管疾病中的研究进展[J].心血管病学进展,2023,(12):1125.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.016]
Li Jun,Li Chunxia,Chen Ruirui,et al.Apolipoprotein C3 in Metabolic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2023,(9):1125.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.016]